Filter by Category: Antimicrobial Surveillance

In vitro activity of meropenem-vaborbactam and characterization of carbapenem resistance mechanisms among carbapenem-resistant Enterobacteriaceae from the 2015 meropenem-vaborbactam surveillance program.

In vitro activity of meropenem-vaborbactam and characterization of carbapenem resistance mechanisms among carbapenem-resistant Enterobacteriaceae from the 2015 meropenem-vaborbactam surveillance program. by Pfaller MA, Huband MD, Mendes RE, Flamm RK and Castanheira M. Int. J. Antimicrob. Agents. 2018: 52 (2); 144-150

In vitro activities of ceftaroline and comparators against Streptococcus pneumoniae isolates from U.S. hospitals: Results from seven years of the AWARE Surveillance Program (2010 to 2016).

In vitro activities of ceftaroline and comparators against Streptococcus pneumoniae isolates from U.S. hospitals: Results from seven years of the AWARE Surveillance Program (2010 to 2016). by Pfaller MA, Mendes RE, Duncan LR, Flamm RK and Sader HS published in Antimicrob. Agents Chemother. 2018 62 (2): e01555

In vitro activity of meropenem-vaborbactam and characterization of carbapenem resistance mechanisms among carbapenem-resistant Enterobacteriaceae from the 2015 meropenem-vaborbactam surveillance program.

In vitro activity of meropenem-vaborbactam and characterization of carbapenem resistance mechanisms among carbapenem-resistant Enterobacteriaceae from the 2015 meropenem-vaborbactam surveillance program. by Pfaller MA, Huband MD, Mendes RE, Flamm RK and Castanheira M publishedin Int. J. Antimicrob. Agents 2018 in press

Antimicrobial activity of dalbavancin against Staphylococcus aureus with decreased susceptibility to flycopeptides, daptomycin, and/or linezolid from U.S. Medical Centers.

Antimicrobial activity of dalbavancin against Staphylococcus aureus with decreased susceptibility to flycopeptides, daptomycin, and/or linezolid from U.S. Medical Centers. by Sader HS, Mendes RE, Duncan LR, Pfaller MA and Flamm RK published in Antimicrob. Agents Chemother. 2018; 62 (3): e02397

Antimicrobial activities of aztreonam-avibactam and comparator agents tested against contemporary (2016) clinical Enterobacteriaceae isolates.

Antimicrobial activities of aztreonam-avibactam and comparator agents tested against contemporary (2016) clinical Enterobacteriaceae isolates. by Sader HS, Mendes RE, Pfaller MA, Shortridge D, Flamm RK and Castanheira M published in Antimicrob. Agents Chemother. 2017; 62 (1): e01856

Antimicrobial activity of ceftolozane-tazobactam tested against Enterobacteriaceae and Pseudomonas aeruginosa with various resistance patterns isolated in U.S. hospitals (2013-2016) as part of the surveillance program: Program to Assess Ceftolozane-Tazobactam Susceptibility.

Antimicrobial activity of ceftolozane-tazobactam tested against Enterobacteriaceae and Pseudomonas aeruginosa with various resistance patterns isolated in U.S. hospitals (2013-2016) as part of the surveillance program: Program to Assess Ceftolozane-Tazobactam Susceptibility. by Shortridge D, Pfaller MA, Castanheira M and Flamm RK published in Microb. Drug Resist. 2018; 24 (5): 563-577

Antimicrobial activity of ceftazidime-avibactam tested against multidrug-resistant Enterobacteriaceae and Pseudomonas aeruginosa isolates from United States medical centers (2013-2016).

Antimicrobial activity of ceftazidime-avibactam tested against multidrug-resistant Enterobacteriaceae and Pseudomonas aeruginosa isolates from United States medical centers (2013-2016). by Sader HS, Castanheira M, Shortridge D, Mendes RE and Flamm RK published in Antimicrob. Agents Chemother. 2017; 61 (11): e01045

Ceftolozane-tazobactam activity against drug-resistant Enterobacteriaceae and Pseudomonas aeruginosa causing healthcare-associated infections in Latin America: Report from an Antimicrobial Surveillance Program (2013-2015).

Ceftolozane-tazobactam activity against drug-resistant Enterobacteriaceae and Pseudomonas aeruginosa causing healthcare-associated infections in Latin America: Report from an Antimicrobial Surveillance Program (2013-2015). by Pfaller MA, Shortridge D, Sader HS, Gales A, Castanheira M and Flamm RK published in Braz. J. Infect. Dis. 2018; in press

Ceftolozane-tazobactam activity against drug-resistant Enterobacteriaceae and Pseudomonas aeruginosa causing health care-associated infections in the Asia-Pacific region (APAC; minus China, Australia and New Zealand): Report from an antimicrobial surveillance program (2013-2015).

Ceftolozane-tazobactam activity against drug-resistant Enterobacteriaceae and Pseudomonas aeruginosa causing health care-associated infections in the Asia-Pacific region (APAC; minus China, Australia and New Zealand): Report from an antimicrobial surveillance program (2013-2015). by Pfaller MA, Shortridge D, Sader HS, Castanheira M and Flamm RK Int. J. Antimicrob. Agents. 2018; 51 (2): 181-189

Activity of omadacycline tested against Streptococcus pneumoniae from a global surveillance program (2014).

Activity of omadacycline tested against Streptococcus pneumoniae from a global surveillance program (2014). by Pfaller MA, Rhomberg PR, Huband MD and Flamm RK published in Diagn. Microbiol. Infect. Dis. 2018; in press